News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Gilead Sciences, Inc. Profit Rises a Higher-than-Expected 21 Percent
April 21, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters - Gilead Sciences Inc (GILD.O) said on Tuesday first-quarter profit rose 21 percent, topping analysts' expectations, on increased sales of its drugs to treat the virus that causes AIDS.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Gilead Sciences, Inc.
MORE ON THIS TOPIC
Vaccines
Moderna’s mRNA Tech Could Boost Flu Shot Efficacy. Americans Will Have To Wait
February 16, 2026
·
3 min read
·
Annalee Armstrong
Earnings
Moderna’s FDA Challenges Stymie Breakeven Goal in ‘Fresh and Fluid’ Situation
February 13, 2026
·
5 min read
·
Annalee Armstrong
Gene therapy
Vertex, CRISPR Set Lofty Goal for Casgevy Gene Therapy as Patient Starts Ramp
February 13, 2026
·
3 min read
·
Dan Samorodnitsky
Obesity
Lilly Prepares $1B+ Orforglipron Stock Ahead of Approval as Novo Brings Wegovy Pill Overseas
February 13, 2026
·
2 min read
·
Tristan Manalac
